One-year Data Support Efficacy and Safety of Abivax’s ABX464 for Ulcerative Colitis

One-year Data Support Efficacy and Safety of Abivax’s ABX464 for Ulcerative Colitis

Abivax has announced data from a long-term trial that continues to support the efficacy and safety of its investigational oral treatment ABX464 for ulcerative colitis (UC).

One year of treatment with daily 50 mg capsules of ABX464 led to the clinical remission of 75% of the patients who had moderate to severe active UC and were enrolled in the company-sponsored open-label trial.  The study's latest results were shared in a late-breaking session of the United European Gastroenterology Week, held recently in Barcelona, Spain. The one-year open-label maintenance study included patients who rolled over from a Phase 2a clinical trial (NCT03093259) that consisted of an induction study in which participants were randomly assigned either 50 mg of ABX464 or a placebo, once a day, for two months (eight weeks). The trial included patients with moderate to severe active UC, who had failed to respond or were intolerant to immunomodulators, anti-TNF biologics, Entyvio, or corticosteroids. A total of 29 patients completed the induction study, and 35% of those given ABX464 were in clinical remission at
Subscribe or to access all post and page content.